Tim Moore - HAVN Life CEO CFO
| HAVLF Stock | USD 0.01 0.00 0.00% |
Insider
Tim Moore is CEO CFO of HAVN Life Sciences
| Age | 65 |
| Phone | 604-687-7130 |
| Web | https://www.havnlife.com |
HAVN Life Management Efficiency
The company has return on total asset (ROA) of (0.3703) % which means that it has lost $0.3703 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (2.3908) %, meaning that it generated substantial loss on money invested by shareholders. HAVN Life's management efficiency ratios could be used to measure how well HAVN Life manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Wolfgang MD | Rigel Pharmaceuticals | 58 | |
| Shengfei Fang | Immutep Ltd ADR | N/A | |
| Jonathan Pachter | Verastem | 66 | |
| Ryan Bloomer | Elevation Oncology | N/A | |
| BPHARM RPh | Verastem | 63 | |
| RPh PharmD | Elevation Oncology | 40 | |
| Stephen JD | Geron | 74 | |
| Christian Mueller | Immutep Ltd ADR | N/A | |
| Erin Cox | Verastem | N/A | |
| Brian Sullivan | Elevation Oncology | N/A | |
| Mba MBA | Verastem | 70 | |
| David Dornan | Elevation Oncology | 46 | |
| Sean Flynn | Verastem | 50 | |
| Joseph Ferra | Elevation Oncology | 49 | |
| Valerie MD | Elevation Oncology | 46 | |
| Daniel Calkins | Verastem | 36 | |
| Robert Weinberg | Verastem | N/A | |
| Piyush Gupta | Verastem | N/A | |
| Michelle MD | Verastem | 48 | |
Management Performance
| Return On Equity | -2.39 | |||
| Return On Asset | -0.37 |
HAVN Life Sciences Management Team
Elected by the shareholders, the HAVN Life's board of directors comprises two types of representatives: HAVN Life inside directors who are chosen from within the company, and outside directors, selected externally and held independent of HAVN. The board's role is to monitor HAVN Life's management team and ensure that shareholders' interests are well served. HAVN Life's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, HAVN Life's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jenna Pozar, Chief Officer | ||
| Tim Moore, CEO CFO | ||
| Paul More, Controller |
HAVN Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is HAVN Life a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.39 | |||
| Return On Asset | -0.37 | |||
| Operating Margin | (7.64) % | |||
| Current Valuation | 626.96 K | |||
| Shares Outstanding | 8.47 M | |||
| Shares Owned By Insiders | 2.77 % | |||
| Price To Book | 0.21 X | |||
| Price To Sales | 0.98 X | |||
| Revenue | 276.47 K | |||
| Gross Profit | 89.69 K |
Currently Active Assets on Macroaxis
Other Information on Investing in HAVN Pink Sheet
HAVN Life financial ratios help investors to determine whether HAVN Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in HAVN with respect to the benefits of owning HAVN Life security.